Company profile

Ticker
DNLI
Exchange
CEO
Ryan J. Watts
Employees
Incorporated
Location
Fiscal year end
SEC CIK

DNLI stock data

(
)

Calendar

7 Aug 20
27 Sep 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
10 Sep 20 Ho Carole Common Stock Sell Dispose S Yes 31 3,689 114.36K 165,141
21 Aug 20 Krognes Steve E. Common Stock Payment of exercise Dispose F No 32.87 1,954 64.23K 1,006,511
21 Aug 20 Schuth Alexander O. Common Stock Payment of exercise Dispose F No 32.88 1,954 64.25K 614,562
21 Aug 20 Ho Carole Common Stock Payment of exercise Dispose F No 32.88 1,954 64.25K 6,511
20 Aug 20 Krognes Steve E. Common Stock Option exercise Aquire M No 0 5,643 0 1,008,465
20 Aug 20 Krognes Steve E. RSU Common Stock Option exercise Dispose M No 0 5,643 0 0
20 Aug 20 Schuth Alexander O. Common Stock Option exercise Aquire M No 0 5,643 0 616,516
20 Aug 20 Schuth Alexander O. RSU Common Stock Option exercise Dispose M No 0 5,643 0 0
20 Aug 20 Ho Carole Common Stock Option exercise Aquire M No 0 5,643 0 8,465
20 Aug 20 Ho Carole RSU Common Stock Option exercise Dispose M No 0 5,643 0 0
77.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 144 126 +14.3%
Opened positions 32 34 -5.9%
Closed positions 14 16 -12.5%
Increased positions 54 52 +3.8%
Reduced positions 35 19 +84.2%
13F shares
Current Prev Q Change
Total value 2.13B 1.78B +19.6%
Total shares 81.67M 79.36M +2.9%
Total puts 13.3K 25.8K -48.4%
Total calls 33.9K 100 +33800.0%
Total put/call ratio 0.4 258.0 -99.8%
Largest owners
Shares Value Change
Crestline Management 13.64M $329.93M -12.4%
Baillie Gifford & Co 9.28M $224.37M +1.6%
Flagship Pioneering 7.98M $192.96M 0.0%
Vanguard 7.09M $171.34M +2.6%
BLK BlackRock 6.26M $151.31M +18.8%
FMR 4.81M $116.41M -7.9%
Temasek 4.41M $106.65M 0.0%
Gilder Gagnon Howe & Co 3.39M $81.86M +3.8%
N Price T Rowe Associates 2.62M $63.4M +116.5%
STT State Street 2.25M $54.29M +32.9%
Largest transactions
Shares Bought/sold Change
Crestline Management 13.64M -1.92M -12.4%
N Price T Rowe Associates 2.62M +1.41M +116.5%
BLK BlackRock 6.26M +991.23K +18.8%
Perceptive Advisors 0 -850K EXIT
STT State Street 2.25M +555.52K +32.9%
Caas Capital Management 1.56M +524.88K +50.9%
Bratton Capital Management 448.04K -505K -53.0%
Ubs Global Asset Management Americas 492.67K +426.53K +644.9%
FMR 4.81M -411.56K -7.9%
Marshall Wace North America 840.88K -323.47K -27.8%

Financial report summary

?
Competition
EisaiMallinckrodtBiogenAstrazenecaRocheShireCytokineticsSanofiAbbVieProthena
Risks
  • Risks Related to Our Business, Financial Condition and Capital Requirements
  • Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
  • Risks Related to Regulatory Approval and Other Legal Compliance Matters
  • Risks Related to Our Reliance on Third Parties
Management Discussion
  • Collaboration revenue was $5.8 million and $9.5 million for the three and six months ended June 30, 2020, respectively, and $4.2 million and $8.4 million for the three and six months ended June 30, 2019, respectively. The increases in collaboration revenue of $1.6 million and $1.1 million for the three and six months ended June 30, 2020, respectively, compared to the comparative period in the prior year were due to increases in revenue from our collaboration with Takeda, driven by increased costs incurred in the programs partnered with Takeda, partially offset by decreases in revenue from our collaboration with Sanofi driven by the fact that revenue for retained activities under the Sanofi Collaboration Agreement are winding down as activities are transferred to Sanofi.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Abeta, adult, antitrust, beta, chronic, customary, death, description, displayed, elderly, encouraging, eukaryotic, heightening, infected, infection, lung, MA, opt, presence, regular, remotely, responding, sixteen, slowdown, sporadic, switching, translation, unique, uptake
Removed: achieved, administrator, amyotrophic, attribution, automatically, Carlo, commitment, consecutive, dividend, emerging, equal, financed, half, intrinsic, lattice, Monte, overlapping, payroll, preceding, recipient, revalued, scheduled, simplified, simulation, stepped, unamortized, unissued, unvested, vested, vesting